Mirtazapina Alter (Mirtazapine)

Mirtazapine works by blocking central presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing serotonin 5‑HT2, 5‑HT3 and histamine H1 receptors. This combined action enhances noradrenergic and serotonergic neurotransmission, alleviating depressive symptoms.

The dosage of Mirtazapina Alter is individualized. A prescriber determines the appropriate starting dose and any subsequent titration based on the patient’s clinical response, tolerability and overall health status.

Safety of mirtazapine in pregnancy and lactation has not been definitively established; it is classified as having an unknown pregnancy category. Use should be considered only when the potential benefits outweigh the risks, and only under medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and the necessary import documentation.

Compared with SSRIs, mirtazapine has a distinct receptor profile that provides strong sedative and appetite‑stimulating effects, which can be beneficial for patients with insomnia or weight loss. However, it may cause more weight gain and sedation, while the risk of serotonin syndrome is lower when combined with other serotonergic agents.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight. Do not refrigerate or expose the product to extreme temperatures, as this could affect tablet integrity.

Mirtazapina Alter is taken orally, usually once daily in the evening, with or without food, as directed by the prescribing clinician. Swallow the tablet whole; do not crush or chew unless specifically instructed by a healthcare professional.

Serious adverse events may include agranulocytosis, severe hypersensitivity reactions, seizures, hepatotoxicity, and the emergence or worsening of suicidal thoughts, especially early in treatment. Patients should be monitored closely for any of these signs.

Individuals with known hypersensitivity to mirtazapine or any of its excipients, patients currently taking MAO inhibitors, and those with uncontrolled cardiovascular disease should avoid using this medication. A clinician must evaluate suitability before prescribing.